ESTRO meets Asia 2024 - Abstract Book

S246

Interdisciplinary – Particle Therapy

ESTRO meets Asia 2024

Conclusion:

In our study, we observed a significant reduction in low dose exposure to the pelvic skeleton, resulting in decreased hematotoxicity with the use of intensity-modulated proton therapy compared to the current standard of care intensity-modulated photon radiotherapy. The rates of sacral insufficiency fractures were comparable to those reported in the literature for IMRT. In light of these findings, we conclude that proton therapy spares bone marrow and is a promising option, especially in cases where concurrent chemotherapy is indicated. A larger prospective phase III study is required to validate these results.

Keywords: Proton therapy, Bone marrow sparing

References:

1. Ellis, R.E.The distribution of active bone marrow in the adult. Phys Med Biol, 1961. 5:416 p. 255-8.

2. Mell, L.K., et al., Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys, 2006. 66(5): p. 1356 65.

3. Arians, N., et al., Prospective phase-II-study evaluating postoperative radiotherapy of cervical and endometrial cancer patients using protons - the APROVE-trial. Radiat Oncol, 2017. 12 (1): p. 188.

345

Proffered Paper

IMPT versus IMRT for anal cancer: Is there a dosimetric advantage to translate to clinical benefit.

Aditi Jain 1 , Rohidas Punde 2 , Yogesh Ghadi 1 , Shivakumar Gudi 1 , Reena Engineer 1 , Rahul Krishnatry 1

1 Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India. 2 Department of Radiation Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India

Purpose/Objective: